- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02481882
Baseline Cortical Haemodynamics in MS (CortHaem)
Investigating Baseline Cortical Haemodynamics in Multiple Sclerosis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
We aim to characterise the underlying cortical haemodynamics in Multiple Sclerosis (MS). We will assess two techniques for measuring blood flow in the brain: arterial spin labelling (ASL) and dynamic susceptibility contrast (DSC) magnetic resonance imaging in the MS patient group. ASL is a non-invasive technique whilst DSC-MR requires the administration of a tracer intravenously. Previous studies have shown conflicting results from these measurements. Reproducibility of ASL and disease activity will also be assessed through repeated scan sessions. Global perfusion in the MS patient group will be compared to a matched healthy control group.
In addition to measuring blood flow using both methods, we will investigate whether differences in perfusion between the MS patient group and the healthy controls can be observed using ASL, and also assess the reproducibility of ASL measurements via repeated scans. These repeated scanning sessions also provide a window to study disease activity in the patient cohort, and patients may be invited to return for up to a total of 4 scanning sessions (with only one involving the use of DSC) to better assess the usefulness of ASL in tracking haemodynamic changes in MS.
Study Regimen:
We aim to recruit 20 MS patients and 20 healthy age-matched controls for this study.
MS Patient Cohort:
The patients will be asked to attend two initial scanning sessions. MS Scan Session 1 will involve the use of the Prohance contrast agent, taking of blood samples and an MRI scan. MS Scan Session 2 will only involve the use of a non-invasive MRI scan.
MS Scan Session 1:
This session will require the administration of a gadolinium contrast agent. Prior to entering the scanner, a cannula is inserted into the patient's arm (cannula A). A small blood sample (5ml) will be taken from all MS patients in order to assess the haematocrit and creatinine content which will be used to determine if they are eligible for gadolinium administration (via use of the POCT i-Stat). This will provide a measure of eGFR which will provide information on the patient's renal function. This will only be performed once per patient and results will be recorded in the CRF. Provided the patient's eGFR is adequate for the study, a second cannula will be inserted into the patient's other arm (cannula B). The patient will enter the scanner with lines attached to both cannulae. The gadolinium bolus will be administered by a clinician in the scan room between scans via cannula A*. During the remainder of the visit, three subsequent blood samples will be taken (up to 5ml each), via cannula B, which will be used to measure gadolinium concentration. Gadolinium administration and blood work will be performed by physicians who are part of the research team with ALS training.
* Gadolinium contrast agents allow for the accurate quantification of blood flow from MR imaging. Prohance (Gadoteridol) is a gadolinium-based fluid administered intravenously to the participant. The contrast agent will be administered by physician with advanced life support (ALS) training. The physician will remain present throughout the duration of the scan and at all times whilst the participant is present at the Sir Peter Mansfield Imaging Centre. In the event of an emergency, a resuscitation kit is readily available. Also, the University's internal emergency phone number is contacted to readily direct emergency services to the site.
MS Scan Session 2:
The patients will be asked to return for MS Scan Session 2 two weeks after completing MS Scan Session 1. Before each scanning session, the patient will be asked to complete and MR safety questionnaire to ensure that no contraindications have arisen between scans. Explanations of what to expect in the MRI scanner environment will be given prior to being asked to sign a consent form. Provided there are no contraindications for the volunteer to enter the scanner, the volunteer will undergo a non-invasive MRI scan lasting approximately 1 hour. No other interventions are to be used. All scanning will be performed using a 7 Tesla Philips Achieva scanner with multi-transit capability (Philips Medical Systems, Best, The Netherlands). The participants will be scanned with a 32-channel receive coil. The subjects will wear-ear plugs, ear defenders and a pulse oximeter (to monitor the pulse) throughout contrast agent administration.
After the completion of MS Scan Sessions 1 and 2, their scans will be analysed and interpreted by a member of the patient's clinical care team. If a patient presents any morphological changes relating to the disease between MS Scan Sessions 1 and 2, the patient will be invited back for an additional 2 scans, labelled as MS Scan Session 3 and 4. If there is no presentation of additional lesions between scans, this will be the end of the patient's participation.
MS Scan Sessions 3 and 4:
These will be identical to MS Scan Session 2 (non-invasive MRI scan only). MS Scan Session 3 will take place at 6 weeks and MS Scan Session 4 will take place at 12 weeks.
Healthy Volunteers:
The healthy volunteers will be asked to attend two scanning sessions (labelled as HV Scan Session 1 and HV Scan Session 2 in the flow chart). Both HV Scan Session 1 and 2 will only involve the use of a non-invasive MRI scan. No gadolinium contrast agent is to be given to the healthy volunteers during this study.
Both HV Scan Session 1 and 2 will be identical to MS Scan Sessions 2, 3 and 4. Upon completing HV Scan Session 1, the healthy volunteer will be invited back for HV Scan Session 2 two weeks later. After completing HV Scan Session 2, the healthy volunteer's participation will be finished.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Nikos Evangelou, Ph.D.
- Phone Number: 0115 970 9735
- Email: nikos.evangelou@nottingham.ac.uk
Study Contact Backup
- Name: Penny A Gowland, Ph.D
- Phone Number: 0115 951 4754
- Email: penny.gowland@nottingham.ac.uk
Study Locations
-
-
Nottinghamshire
-
Nottingham, Nottinghamshire, United Kingdom, NG7 2RD
- Recruiting
- Queen's Medical Centre
-
Contact:
- Nikos Evangelou
- Phone Number: 0115 9709735
- Email: nikos.evangelou@nottingham.ac.uk
-
Contact:
- Yasser Falah
- Phone Number: 0115 924 9924
- Email: yasser.falah@nottingham.ac.uk
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria (Healthy Volunteers):
- Male or female volunteers who are between the ages of 21 and 80.
- Able to give voluntary written informed consent to participate in the study.
- Able to understand the requirements of the study, including anonymous publication, and agree to co-operate with the study procedures.
Inclusion Criteria (Patients):
- Diagnosed with Multiple Sclerosis.
- Male or female volunteers who are between the ages of 21 and 80.
- Able to give voluntary written informed consent to participate in the study.
- Able to understand the requirements of the study, including anonymous publication, and agree to co-operate with the study procedures.
Exclusion Criteria:
- Any history of neurological illness other than MS.
- Known hypersensitivity to any MR or X-Ray contrast agent.
- Any history of renal failure or disease.
- Any history of allergies.
- Any history of circulation problems (vascular disease).
- Pregnancy or breastfeeding.
- MRI contraindications as screened on safety questionnaire (e.g. metal implants or pacemaker).
- Have taken part in any other clinical study within the previous 3 months.#
- Any contraindications provided from MRI or contrast agent safety forms.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Healthy Volunteers
Healthy Volunteers will undergo an Magnetic Resonance Imaging scan.
|
All scanning will be performed using a 7 Tesla Philips Achieva scanner with multi-transit capability (Philips Medical Systems, Best, The Netherlands).
The volunteers will be scanned with a 32-channel receive coil.
|
Other: MS Patients
Patients will undergo and Magnetic Resonance Imaging scan including the use of Prohance (Gadoteridol).
|
All scanning will be performed using a 7 Tesla Philips Achieva scanner with multi-transit capability (Philips Medical Systems, Best, The Netherlands).
The volunteers will be scanned with a 32-channel receive coil.
A gadolinium based liquid administered intravenously in order to quantify blood flow in the brain using an MR scanner.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cerebral Blood Flow
Time Frame: 1 hour
|
A short MRI scan is able to quantify the amount of blood perfusion into brain tissue (to be performed with and without the gadolinium contrast agent).
|
1 hour
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Arterial Cerebral Blood Volume
Time Frame: 1 hour
|
A short MRI scan is able to quantify the volume of arterial blood in a volume of brain tissue.
|
1 hour
|
Arterial Transit Time
Time Frame: 1 hour
|
A short MRI scan is able to quantify the amount of time taken for blood to reach an area of the brain.
|
1 hour
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Nikos Evangelou, Ph.D., Faculty of Medicine & Health Sciences
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 15037
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsRecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.RecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on Magnetic Resonance Imaging
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingProstate Adenocarcinoma | Prostate CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Recruiting
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityRecruitingIntracranial NeoplasmUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Healthy SubjectUnited States
-
Stanford UniversityTerminatedLaryngeal Neoplasms | Head and Neck Cancers | Larynx CancerUnited States
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)CompletedBreast CancerUnited States
-
University of California, San FranciscoTerminatedAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
Abramson Cancer Center of the University of PennsylvaniaCompletedBrain TumorUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedThoracic Spine NeoplasmUnited States